Loading
Gilead Sciences, Inc. Stock: price and insider trades · United States
Gilead Sciences, Inc.: what insiders have been doing
This page follows insider dealings at Gilead Sciences, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Foster City, United States. The group dates from 1987. Its latest reported headcount is 17,000 employees (2026). Between 18 October 2025 and 18 October 2026, 15 insiders published 117 filings.
Only sales appear on the open market, 45 sales in all totalling €20.7M, filed by 5 insiders. No amount is published for 4 filings, which the totals therefore leave out. The largest single trade was a sale of €2.0M by Mercier Johanna, published on 18 August 2026, equal to 0.0012% of the market capitalisation.
Compared with its exchange (5,458 companies, median 22 filings), a count of 117 filings is above the norm. Our records for Gilead Sciences, Inc. go back to 2016, with no purchases and 94 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 29.44 bn USD and net income of 8.51 bn USD, with a dividend of 3.16 USD per share.
Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
368
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€38M
94 ops. · all time
Who traded when
BuySaleAndrew D. Dickinson22 sales
Johanna Mercier19 sales
Daniel Patrick O'Day16 sales
Bluestone Jeffrey6 sales
Anthony Welters4 sales
Analyst consensus: bullish or bearish?
Analysts rate Gilead Sciences, Inc. Buy (bullish), based on 26 analysts. Average price target: US$158.65.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,104 of 24,166 companies
57.7
score / 100
Value54
Quality62
FCF yld5.0%
Earn yld4.5%
EV/EBITDA15.6x
ROE-21%
Gross mgn79%
Net mgn29%
Debt/EBITDA1.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$151.28
Analyst consensus
26 analystsBuy
US$123.00Target US$158.65(+5%)US$180.00
Income statement
RevenueUS$29.4B
Gross profitUS$23.2B79% margin
EBITDAUS$13.6B46% margin
Net incomeUS$8.5B-10.6% margin
Valuation
PER (trailing)17.9x
PER (forward)15.3x
P/Book15.9x
Beta0.35
Balance sheet & cash
Market capUS$187.6B
Total debtUS$24.9B
Free Cash FlowUS$9.5B
Debt / Equity223%
Profitability & ownership
ROE-20.7%
ROA14.1%
% insiders0.1%
% institutions92.2%
Last declaration on 16 October 2026
Declarations368 total
3,000 shares@ US$156.220.0002% mcap2.6% of flowCommon StockSEC:0001310204-26-000031:0
3,000 shares@ US$156.220.0002% mcap2.6% of flowCommon StockSEC:0001782135-26-000035:0
3,000 shares@ US$156.220.0002% mcap23.0% of flowCommonSEC144:0001950047-26-010246
3,000 shares@ US$156.220.0002% mcap8.7% of flowCommonSEC144:0001950047-26-010250
12,000 shares@ US$147.7190.0009% mcap6.2% of flowCommon StockSEC:0001638643-26-000035:0
3,000 shares@ US$148.62650.0002% mcap1.6% of flowCommon StockSEC:0001638643-26-000035:1
2,223 sharesCommon StockSEC:0001927648-26-000005:0
768 shares@ US$152.670.0001% mcap100.0% of flowCommon StockSEC:0001927648-26-000005:1
3,000 shares@ US$145.290.0002% mcap2.4% of flowCommon StockSEC:0001310204-26-000029:0
1,600 shares@ US$143.69170.0001% mcap1.3% of flowCommon StockSEC:0001782135-26-000033:0
800 shares@ US$144.45690.0001% mcap0.6% of flowCommon StockSEC:0001782135-26-000033:1
600 shares@ US$145.290.0000% mcap0.5% of flowCommon StockSEC:0001782135-26-000033:2
3,000 shares@ US$145.290.0002% mcap27.0% of flowCommonSEC144:0001950047-26-009467
3,000 shares@ US$144.21540.0002% mcap8.6% of flowCommonSEC144:0001950047-26-009482
533 sharesCommon StockSEC:0001739515-26-000011:0
8,780 sharesCommon StockSEC:0001638643-26-000033:0
2,797 sharesCommon StockSEC:0001782135-26-000031:0
590 sharesCommon StockSEC:0002110603-26-000013:0
2,797 sharesCommon StockSEC:0001310204-26-000027:0
4,230 shares@ US$144.810.0003% mcap2.3% of flowCommon StockSEC:0001638643-26-000033:1
263 shares@ US$144.810.0000% mcap100.0% of flowCommon StockSEC:0001739515-26-000011:1
1,347 shares@ US$144.810.0001% mcap1.1% of flowCommon StockSEC:0001310204-26-000027:1
1,347 shares@ US$144.810.0001% mcap1.1% of flowCommon StockSEC:0001782135-26-000031:1
285 shares@ US$144.810.0000% mcap9.6% of flowCommon StockSEC:0002110603-26-000013:1
7,718 shares@ US$60.670.0002% mcap12.4% of flowCommon StockSEC:0001213307-26-000005:0
25 of 368 declarations
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker GILD, with its corporate headquarters in Foster City, California, United States. Founded in 1987, Gilead built its reputation in antiviral medicines and has since broadened its strategy into oncology and inflammation. The company’s legacy and current market standing are anchored in virology, especially HIV, while its liver disease franchise and oncology platform have become important contributors to the long-term investment case. ([gilead.com](https://www.gilead.com/contact?utm_source=openai))
From a business-model perspective, Gilead combines high-value specialty pharmaceutical commercialization with a deep R&D engine and a global development, manufacturing, and regulatory footprint. Its main therapeutic areas include HIV, liver disease, oncology, and, increasingly, inflammation. Key marketed products and programs include Biktarvy and Descovy in HIV, Veklury in certain COVID-19-related settings, Trodelvy in oncology, and Yeztugo, which Gilead describes as the first twice-yearly HIV prevention therapy. The company is also advancing next-generation programs, including bictegravir/lenacapavir combinations and a broader pipeline in hematology, cell therapy, and immunology. ([gilead.com](https://www.gilead.com/news/news-details/2026/gilead-sciences-announces-fourth-quarter-and-full-year-2025-financial-results?utm_source=openai))
Read moreShow less
Gilead’s competitive position is that of a large-cap biotech with durable franchises, strong regulatory moats, and significant commercial execution capabilities. At the same time, it remains exposed to the classic biopharma risks: pricing pressure, reimbursement challenges, and patent or lifecycle risk on mature products. The company operates internationally in more than 35 countries, while maintaining a substantial U.S. industrial and scientific base. Its U.S. footprint includes manufacturing, packaging, labeling, and distribution activities, with Foster City serving as the worldwide headquarters and ongoing investment in domestic research and manufacturing capacity. ([gilead.com](https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel?utm_source=openai))
Recent developments highlight a more expansionary strategic phase. In 2026, Gilead reported full-year 2025 results showing growth in HIV and liver disease sales and announced a quarterly dividend increase. The company also pursued targeted M&A and pipeline expansion, including the announced acquisition of Tubulis and the Arcellx transaction, while the FDA granted priority review for a bictegravir/lenacapavir HIV treatment application. In parallel, Gilead and its partners continued to expand access initiatives for lenacapavir for HIV prevention. Overall, Gilead remains a major U.S. healthcare name on the NASDAQ with a mix of established cash-generating franchises and meaningful pipeline optionality. ([investors.gilead.com](https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
